Published on
June 27, 2023
- 17:45 GMT
Withdrawn application: Lagevrio, molnupiravir, Date of withdrawal: 21/06/2023, Initial authorisation
At the time of the withdrawal, the Agency’s human medicines committee (CHMP) had recommended refusing marketing authorisation for Lagevrio for the treatment of adults with COVID-19. Having evaluated the data provided by the company, the CHMP had concluded …
Distribution channels:
Healthcare & Pharmaceuticals Industry
